Trials / Withdrawn
WithdrawnNCT03228043
Apatinib for Resectable Colorectal Cancer
Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer
- Status
- Withdrawn
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Nanchong Central Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively. Language: English.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib | Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal |
| DRUG | CAPEOX | CAPEOX adjuvant chemotherapy for resectable colorectal |
Timeline
- Start date
- 2020-03-01
- Primary completion
- 2021-03-01
- Completion
- 2023-03-01
- First posted
- 2017-07-24
- Last updated
- 2024-11-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03228043. Inclusion in this directory is not an endorsement.